Τρίτη 5 Νοεμβρίου 2013
Immunizing Infants at 'Sick' Visits: Good or Bad Idea?
Immunizing Infants at 'Sick' Visits: Good or Bad Idea?
William T. Basco, Jr., MD, MS
October 01, 2013Sick-Visit Immunizations and Delayed Well-Baby Visits
Robison SG
Pediatrics. 2013;132:44-48
Pediatrics. 2013;132:44-48
Well- vs Sick-Visit Vaccination
For much of the past 2 decades, the American Academy of Pediatrics and the Centers for Disease Control and Prevention have recommended immunizing children at any provider visit, including sick visits. The primary rationale for sick-visit immunization is that it avoids "missed opportunities" to vaccinate, reducing the time during which a child may be at risk for infectious diseases if they do not attend scheduled well visits (where immunizations are typically delivered). However, there is concern that immunizing at sick visits will prompt parents to skip well visits that might have been due around the time of the sick visit. Of note, the recommendation to vaccinate even at sick visits was intended for patients with mild illnesses, such as upper respiratory tract infections or even otitis media. It's also worth emphasizing that the presence of fever did not necessarily constitute a contraindication to vaccination.
Study Summary
To evaluate the relationship among these potentially opposing issues, Robison evaluated children who experienced a sick visit for acute otitis media (AOM) around the time that well-baby visits would typically be scheduled, at 2, 4, or 6 months of age. Whether the receipt of vaccinations at the sick visit for AOM correlated with a lower frequency of subsequent well-baby visits was evaluated, focusing on whether the child who was seen for AOM also returned for the well-child visit corresponding to the infant's age. For example, if a child had a sick visit for AOM at 6 months of age and received vaccinations, did the child return for a 6-month well-child check?
Infants were matched with control infants on the basis of demographics and medical history before the AOM visit, and immunizations and well-baby checks completed by 2 years of age were compared between these 2 groups. The frequency of make-up well-baby checks after AOM visits where vaccination was not given was also evaluated. All infants were born in 2007 and enrolled in the Oregon Health Plan. Claims data and state registry immunization data were used to answer study questions. For vaccination status, the study focused on receipt of the DTaP (diphtheria-tetanus-acellular pertussis) vaccine because other studies showed that receipt of DTaP is representative of overall vaccination status. Moreover, focusing on 1 vaccine addressed the issue of potential voluntary spreading of the vaccine schedule by parents or providers. A case was any child who received DTaP at his or her visit for AOM. A make-up well-baby examination was any well-child visit that occurred within 4 weeks of the AOM visit, matched to the patient's age (2, 4, or 6 months). In addition to evaluating immunization status at 19 and 24 months, the total number of well visits made between 2 and 24 months of age was determined.
Study Findings
More than 21,000 infants were born in 2007, with more than 6500 infants having a visit for AOM in the first 12 months of life. Slightly more than 1000 infants made an AOM visit around the age of 2, 4, or 6 months. The demographics of this case group were 67% white, 30% Hispanic, and 3% nonwhite, non-Hispanic. Among case infants who made a visit for AOM at 2, 4, or 6 months, only 7.5% received a DTaP vaccine at the sick visit. Furthermore, 56.7% of these infants did not receive a vaccination but made a well-child visit within 5 weeks. Finally, 35.8% of the case infants had neither a sick-visit shot nor a make-up well-child visit within the 4-week period.
Case infants who received a vaccination at the AOM visit made an average of 4.7 well-child visits vs 4.5 well-child visits among those who were not vaccinated at the AOM visit, a difference that was not significant. Case infants who did not receive vaccination at the AOM visit but attended a make-up well-child visit within 4 weeks made an average of 5 well-baby visits overall, a number that was not significantly different from the control group. However, case infants who did not receive a vaccination or attend a make-up visit (36% of the total case infants) made an average of only 3.8 well-baby visits, significantly fewer than all other groups. The only infants at significantly higher risk of not being up-to-date on their immunizations were those who had no vaccination at the AOM visit and made no make-up visit within 4 weeks. The immunization status of all other infants was similar at 19 and 24 months. Robison concluded that this study did not find a reduction in number of vaccines received or well-baby visits made in children who received a DTaP vaccination at a sick visit for AOM.
Viewpoint
Whether a child attends a make-up well-baby visit within 4 weeks of a sick visit seems to be the most important factor in this study. Practitioners should take 2 messages from these findings. First, the study suggests that vaccination at sick visits, at least at visits for AOM, does not appear to reduce the later receipt of vaccines or the number of well-baby visits. However, the study also suggests that, regardless of whether the practitioner supports immunizing at sick visits, scheduling a needed well-baby visit quickly after the sick visit is important to both immunization status and the number of well-baby visits made by the child.
Vaccination Recommendations for the 2013-2014 Influenza Season
Vaccination Recommendations for the 2013-2014 Influenza Season
Joseph Bresee, MD
September 27, 2013Changes to This Season's Vaccine Recommendations
Hello. I am Dr. Joe Bresee from CDC's Influenza Division. I am pleased to speak with you today as part of the CDC Expert Commentary Series.
Today I will discuss vaccination recommendations for the 2013-2014 influenza season. Of greatest importance, CDC continues to recommend that everyone 6 months and older receive a yearly flu vaccine, with rare exceptions. But there are some changes to this season's recommendations, which is what I will be focusing on in this commentary. First I will discuss the vaccine options available in the United States. This season, some quadrivalent vaccines will be available, along with the trivalent vaccine, which has been available for decades. The trivalent flu vaccine contains 3 antigens: an influenza A (H1N1) virus, an influenza A (H3N2) virus, and an influenza B virus. The quadrivalent vaccine contains these 3 and a second B antigen. All nasal spray vaccines this season will be quadrivalent. Inactivated flu vaccines, which are administered as intramuscular and intradermal injections, will be available in both trivalent and quadrivalent formulations. Most of the flu shots available this season will be trivalent vaccines. There is no need to delay vaccination if the quadrivalent vaccine is not available, because both types of vaccine offer important protection from flu. Trivalent flu vaccines are available as:
• A standard-dose injection approved for use in people ages 6 months and older, including those with high-risk medical conditions and pregnant women;
• A high-dose injection approved for use in people 65 years and older;
• An intradermal injection that is approved for use in people 18 through 64 years of age and uses a much smaller needle than the regular flu shot;
• A standard-dose, cell-based flu shot for use in people 18 years and older;
• A recombinant, egg-free shot approved for use in people between 18 and 49 years; and
• A nasal spray (or intranasal) vaccine, approved for healthy people ages 2-49 who do not have an underlying medical condition, such as asthma or diabetes, that predisposes them to serious influenza complications.
For a complete list of available vaccines along with trade names, manufacturers, presentations, mercury content, age indications, and routes, see this list of seasonal vaccines. This year, vaccine shipments began in late July and will continue until all vaccine is distributed. Manufacturers have projected that they will produce between 135 million and 139 million doses of influenza vaccine for use in the United States this flu season.
There is no preferential recommendation for any type or brand of licensed influenza vaccine over another. Different formulations are available from various manufacturers, so clinicians should refer to the package inserts for the recommended age groups, contraindications, and precautions for each vaccine.
Flu Vaccines for Young Children
Now I will briefly talk about dose recommendations for young children. The following children will require 2 doses of influenza vaccine, administered at least 4 weeks apart, for full protection:
• Children aged 6 months to 8 years who have never been vaccinated against influenza or for whom vaccination history is unknown; and
• Children who have not previously received at least 2 doses of seasonal vaccine and at least 1 dose of pandemic 2009(H1N1)-containing vaccine;
• Children who have received at least 2 doses of seasonal vaccine and at least 1 dose of pandemic 2009(H1N1) vaccine previously will need only 1 dose this season.
The Advisory Committee on Immunization Practices has developed an algorithm that might be helpful in determining the number of doses needed.
Finally, I would like to say a word about egg allergies. Although the nasal spray vaccine should not be used in patients with allergy to eggs, other safe flu vaccine options are available.
People with mild allergies to egg -- specifically, people who experience only hives in response to egg exposure -- may receive either recombinant or inactivated influenza vaccine. The recombinant vaccine, FluBlok®, is egg-free and is approved for people 18-49 years old who have no other contraindications. Inactivated (egg- or cell-culture based) vaccine may also be used, as long as the vaccine is administered by a healthcare provider who is familiar with the potential manifestations of egg allergies, and the recipient can be observed by a healthcare professional for at least 30 minutes after receiving each dose.
Egg-allergic people who have experienced any symptoms other than hives after egg exposure also may receive recombinant vaccine if they are between the ages of 18 and 49 and have no other contraindications. If recombinant vaccine is not available or if the recipient is not 18 through 49 years old, referral to an allergy expert should be obtained prior to vaccination.
In closing, your recommendation to your patients that they get vaccinated is more effective in increasing acceptance of vaccination than any other influencing factor. The CDC Influenza Free Resources includes brochures, posters, fact sheets, customizable reminder cards, and social media tools that are all designed to help you educate and reach your patients with a reminder to get vaccinated.
Is Limitation of Hip Abduction a Useful Clinical Sign in the Diagnosis of Developmental Dysplasia of the Hip?
Is Limitation of Hip Abduction a Useful Clinical Sign in the Diagnosis of Developmental Dysplasia of the Hip?
Q Choudry, R Goyal, R W Paton
Arch Dis Child. 2013;98(11):862-866.
Abstract and Introduction
Abstract
Aim The relationship between the presence and severity of sonographically diagnosed developmental dysplasia of the hip (DDH) and the clinical abnormality of limitation of hip abduction (LHA) was investigated.
Methods A prospective, longitudinal, selective 'at risk' and neonatal instability hip ultrasound programme between 1 January 1996 and 31 December 2005. 2876 neonates/infants were initially screened for DDH by clinical examination and by hip ultrasound imaging. Pathological sonographically evaluated DDH was considered to be Graf Type III, IV and irreducible hip dislocation. Inclusion criteria were cases of unilateral or bilateral limitation of hip abduction hip. Exclusion criteria: syndromal, neuromuscular and skeletal dysplasia cases.
Results 492 children presented with LHA (55 unilateral LHA). The mean age of neonates/infants with either unilateral or bilateral LHA was significantly higher than those without (p<0.001). In the sonographic diagnosis of Graf Type III and IV dysplasias, unilateral LHA had a PPV of 40% compared with only 0.3% for bilateral LHA. The sensitivity of unilateral LHA increased to 78.3% and a PPV 54.7% after the age of 8 weeks for Graf Types III, IV and irreducible hip dislocation.
Conclusions This study identifies a time-dependent association with unilateral LHA in the diagnosis of 'pathological' DDH after the age of 8 weeks. The presence of bilateral LHA in the young infant may be a normal variant and is an inaccurate clinical sign in the diagnosis of pathological DDH. LHA should be actively sought after 8 weeks of age and if present should be followed by a formal ultrasound or radiographic examination to confirm whether or not the hip is developing in a satisfactory manner.
Introduction
The relationship between the presence and severity of sonographically diagnosed developmental dysplasia of the hip (DDH) and the clinical abnormality of limitation of hip abduction (LHA) of the affected hip is currently controversial.[1] It is generally accepted that LHA is associated with irreducible or late diagnosed dislocation.[2] There may be difficulty in detecting this clinical sign accurately.[3] Terjesen felt that LHA was the most important clinical sign of a pathological hip in DDH.[3] Stoffelen et al [4]was of the opinion that there was a link between LHA and hip dysplasia.
In a previous 5-year prospective longitudinal observational study, we suggested that if unilateral LHA is detected clinically, at 3–4 months of age, further investigation is warranted.[1] By contrast, it was noted that the presence of bilateral LHA was a poor clinical sign due to its lack of sensitivity. In this previous study, positive predictive value (PPV) was not calculated and there was a lack of data for 14% of the cases in the series, weakening its accuracy and value.
This 10-year longitudinal observational study investigated the relationship and development of LHA with DDH as demonstrated by ultrasound imaging and/or radiographs (if irreducible). It has the advantage of increased numbers and of better data collection and analysis than the previous 5-year study.[1]
Patients and Methods
Between 1 January 1996 and 31 December 2005, a prospective, observational longitudinal, targeted (clinical instability and 'at risk') hip ultrasound and clinical screening programme was undertaken at Blackburn Royal Infirmary. Neonates referred with clinical instability (as defined by a positive Ortolani or Barlow manoeuvre) were assessed by ultrasound within 1–2 weeks of age while infants considered to be 'at-risk' were assessed between 6 and 9 weeks of age. Other cases could be referred at any time from the community, usually after the 6-week general practitioner 'hip check' for clinical instability or limited hip abduction. The majority of referrals were in a bimodal distribution (within 1–2 weeks and at between 6 and 9 weeks). 'At risk' factors included a strong family history, breech presentation, postural and fixed foot abnormalities, oligohydramnios and torticollis.[5] Infants presenting later (usually referred from the general practitioner) with LHA were assessed clinically and with sonographic and/or radiographic hip joint imaging (depending on age of presentation).
During the 10-year study period, 2876 (7.66% of the birth population) neonatal instability and 'at-risk' patients were assessed by the senior author (RWP), clinically and ultrasonographically, from a total of 37 518 births from the surrounding districts of Blackburn, Hyndburn and the Ribble Valley. The clinical assessment of hip abduction was made with the patient supine with both hips flexed to 90°. The prone method was not used as the senior author (RWP) found it was difficult to fix the pelvis, making accurate assessment poor. The clinical examination was undertaken independently of the ultrasound hip scan. LHA was noted at this initial assessment, and any block to full abduction was noted from the horizontal and was considered clinically present if it was estimated to be equal to or more than 20° compared to the other hip, as less than this has been shown to be within the normal range.[1,6] Clinically, it is difficult to detect a difference between both hips in unilateral LHA of less than 20°; however, no assessment was made regarding the absolute degree of limited abduction and dysplasia as this sign was considered as positive if >20° or negative if <20°. Inclusion criteria were cases of unilateral or bilateral limitation of hip abduction hip (excluding syndromal, neuromuscular and skeletal dysplasia cases).
Ultrasound examinations were undertaken with the patient in the lateral decubitus position, with the hips flexed and adducted, in order to potentially minimise errors produced by pelvic obliquity. Static[7] and dynamic[8] (incorporating the Barlow's dynamic manoeuvre to demonstrate instability) sonographic hip imaging methods were used and the Graf α angle, measuring the osseous development of the acetabular roof, was recorded. The Graf α angle is the angle subtended by two lines, a baseline running tangentially to the wall of the ilium and an acetabular roof line. A modification of these sonographic measurements[1] was used (Figure 1).
Figure 1.
Illustration of the α angle denoting the slope of the bony acetabulum. A modified Graf classification used; Type I (normal) α angle >60°, Type II α angle 43–59°, Type III α angle <43°, Type IV subluxable, dislocated dislocatable hip.
'Pathological' sonographic DDH was considered to be Graf Type III, IV or hip joint irreducibility.[1,5] As 90% of Graf Type II dysplasia spontaneously resolve, the majority of Graf Type II hips were considered to be 'physiological'.[9–11] All Graf Type II hips were followed up until normal or treated if they deteriorated. If the sonographic hip dysplasia deteriorated, the worst classification was recorded in the data analysis (ie, Graf Type III rather than Graf Type II).
Any infant, who presented after the age of 4–6 months with LHA, was initially assessed with a plain pelvic radiograph (although the hip was in addition imaged sonographically if the child was below 40 weeks old). In these cases, the diagnosis of pathological hip dysplasia was made using the radiological maturation curve of Tonnis[12] in which a pathological hip dysplasia was diagnosed if the acetabular index was below two SD of the mean for that age (the lowest 2.5% of the population).
The study was not completed until 4 years after 31 December 2005, in order to identify other cases of irreducible hip dislocation or 'pathological' dysplasia requiring surgery which were born within the 10 years of the study but which presented to the clinic at a later date (ie, 'late' cases).
Statistical analysis was conducted using XLstat comparing the three main groups of patients, namely unilateral LHA, bilateral LHA and no LHA to determine the sensitivity, specificity of the tests as well as the PPV and negative predictive values (NPV) of LHA.
Results
Limited Hip Abduction
A total of 2876 patients were examined clinically and with hip ultrasound imaging over the study period. Of these, 492 patients (17%) had LHA with 2384 patients (83%) being normal with no limitation of hip abduction on the initial clinical assessment. The sonographic hip imaging results are presented in Figure 2.
Figure 2.
Algorithm of limited hip abduction (LHA) and the ultrasound hip imaging results.
In the total sample of the 'at risk' or unstable hips (5752 hip joints), initial ultrasound showed that 5314 (92.4%) were normal, 282 (4.9%) were Graf Type II, 34 (0.6%) were Graf Type III and 122 (2.1%) were Graf Type IV. Of the 122 Graf Type IV hips (92 patients), 8 (6.6%) were in the unilateral LHA group (all on the clinically abnormal hip), 2 (1.6%) were in the bilateral LHA group (two different patients each having one hip affected) and the remaining 112 (91.8%) in the no LHA group. There were 62 patients with unilateral Graf Type IV and 30 with bilateral Graf Type IV hips (subluxation or dislocation).
The mean age of patients (regardless of the presence or absence of dysplasia and including those presenting late) were unilateral LHA group 131.5 days (95% CI 108.3 to 154.7 days), bilateral LHA group 79.1 days (95% CI 75.6 to 82.5 days) and no LHA group 44.2 days (95% CI 39.9 to 49.7 days). The difference between the ages in the unilateral and bilateral LHA group and the no LHA group was significant (p<0.0001).
If unilateral LHA is only assessed with cases of 'pathological' DDH presenting after the age of 8 weeks (Graf Type III, IV and irreducible hip dislocation), the sensitivity was 78.3%, the specificity was 92.9%, the PPV was 54.7% and the NPV was 97.3%. As the diagnosis of sonographic 'pathological' DDH is likely to have fewer false positive and negative cases, these results are likely be more accurate than if all sonographic dysplasias are assessed in the analysis.
In the no LHA group, there were 82 patients (52 unilateral and 30 bilateral) with 112 Graf Type IV hips (mean age 11.3 days 95% CI±8 days). All the Graf Type IV hips were 'early' dislocatable (within weeks) with only two patients (two hips) requiring later open reduction for failed conservative treatment in a Pavlik harness.
In the bilateral LHA group, there were two patients each presenting with one Graf Type IV hip.
As a clinical screening test the sensitivities, specificities, PPVs and NPVs for unilateral and bilateral LHA as well as the values for unilateral LHA according to age are shown in .
Table 1. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for unilateral and bilateral LHA and dysplasia of the hip
| Dysplasia | Sensitivity % | Specificity % | PPV % | NPV % |
|---|---|---|---|---|
| Unilateral LHA Type III, IV (n=23) | 14.4 | 99.3 | 40 | 97.3 |
| Bilateral LHA Type III, IV (n=3) | 2.2 | 41.1 | 0.3 | 81.8 |
| Unilateral LHA Type III, IV Age <8 weeks (n=0) | 0 | 97.5 | 0 | 73.6 |
| Unilateral LHA Type III, IV Age >8 weeks (n=23) | 78.3 | 92.9 | 54.7 | 97.5 |
In this 10-year study, the overall dislocation rate requiring open reduction was 0.53–0.59 per 1000 (20 infants/22 hips) and including the surgical treatment of persistent pathological radiological dysplasia the rate was 0.69 per 100 (26 cases). The two bilateral irreducible hip dislocations (1:18 759) both presented after the age of 11 months. Ninety-five per cent of the irreducible hips were identified in females (19 out of 20), whereas in late dysplasia requiring surgery, the 83.34% were in males (5 out of 6). Surprisingly of the 20 irreducible hips, 40% (8 cases) were diagnosed before 3 months (of age), 20% (4 cases) at 3–6 months, 5% (1 case) at 6–12 months and 35% (7 cases) between 12 and 20 months. No cases of irreducible dislocation were diagnosed after 20 months of age.
Discussion
Despite a paucity of evidence supporting its value in improving outcomes, universal clinical screening for DDH, with or without the addition of selective or universal ultrasound hip imaging, remains a well-established method for its detection.[13,14]
Klisic[15] described DDH as a range of hip disorders ranging between dysplasia and irreducible dislocation. This is a dynamic condition in which there can be resolution or deterioration of hip instability or dysplasias. Klisic's[15] definition of DDH includes physiological (or immature) dysplasias (Graf Type II) that generally resolve without treatment. This has resulted in an inconsistency in the literature, as some studies include Graf Type II dysplasias as pathological resulting in high diagnostic and treatment rates of 5–7%. The term DDH does not include neurological, syndromal or neuromuscular cases.[16]
The lack of a practical confirmatory 'gold-standard' clinical or sonographic diagnostic test coupled with a consistent lack of 'known' risk factors in between 69% to 73% of cases makes identification of pathological DDH difficult.[5,17] Clinical examination using provocative tests such as the Ortolani or Barlow manoeuvres continue to be the mainstay of initial diagnosis.[18] These clinical tests are not reliable enough to be considered to be an ideal screening method and should be considered surveillance.[19] Within 1 month of age, 88% of clinically diagnosed neonatal unstable hip joints may spontaneously stabilise.[20] There are very little reliable data on the natural history of Graf Type III hip dysplasia. However, some Graf Type III hips may spontaneously resolve.[9] If this is added to the vague definition of DDH,[18] there is some doubt on what constitutes 'true' pathological DDH. This makes research into this subject difficult and possibly subjective. Some consider the only 'true' pathology in DDH is the rate of irreducible dislocation of the hip.[5] The rate of irreducible hip dislocation in this study is consistent with the best universal clinical or selective screening programmes.[5,21] There is no internationally agreed definition of 'pathological' DDH. However, the general consensus is that in neonatal and infant DDH Graf Type III, IV and irreducible hip dislocation should be treated as pathological.[1,5] Screening for 'pathological' hip dysplasia is not possible as the true incidence or prevalence of this condition in the adult is unknown. The relationship between adult acetabular dysplasia (diagnosed radio logically) and neonatal hip dysplasia (diagnosed sonographically) is unknown. Although up to 30% of total hip replacements are thought to be related to adult hip dysplasia,[22,23] there is no direct proven relationship with neonatal sonographic acetabular abnormalities.
Additional physical signs previously considered to be associated with DDH, including asymmetrical thigh and gluteal skin folds, have little value in diagnosis.[14,15,20,24]
The numbers (%) of 'pathological' sonographic hip dysplasias and/or hip instability from this study are within the accepted range published within the literature.[25] The relationship between LHA and DDH remains controversial. Previous reports have suggested a link with worsening limitation,[4] less severe dysplasia[26] or even dysplasia in the contralateral hip.[27] The definition of LHA may be vague, and like the Ortolani/Barlow manoeuvres, a positive or negative result may suffice in these rather subjective tests. The sonographic hip imaging and clinical hip examinations was undertaken by the same examiner. This increases the likelihood of unintentional bias though this was unavoidable in this study as the clinic was Consultant based (RWP). The senior author, however, has over 20 years experience, and his ultrasonography image quality and interpretation have been independently validated as accurate. Selective 'screening' for DDH (clinical examination combined with hip sonography) is unusual with few orthopaedic practitioners undertaking this in the UK. As in Ortolani/Barlow manoeuvres, the experience of the examiner may be an important factor in the accurate diagnosis of LHA. Irritable infants can make examination difficult or allow for inaccurate recording in inexperienced hands.
While LHA has been identified to be present in DDH, the onset of the sign has not been accurately identified. In our previous study,[1] we noted a low level of LHA in the 'early' dislocatable (5.9%) group compared with those that presented late (87.5%) or early irreducible group (100%). Neonatal laxity is likely to be the reason for the absence of LHA in the neonate.[28] The lack of LHA in the newborn in DDH should be differentiated from the so-called moulded baby syndrome in which LHA is present at birth along with pelvic obliquity, scoliosis, plagiocephaly and postural foot abnormalities. In this condition while LHA is present at birth, there is no association with DDH and ultimately no further treatment is required for the hips.[29,30]
Sixty per cent of the irreducible hip dislocations presented after the age of 3 months. This confirms the failure of universal neonatal and 6-week General Practitioner (GP) clinical screening guidelines in addition to selective at risk sonographic hip screening in identifying and preventing the majority of irreducible hip dislocations.
Our study has shown that the sensitivity of this test was low when all types of sonographic dysplasia are included in the analysis, suggesting that LHA is not exclusive to 'pathological' DDH. Its value, however, markedly increased after the age of 8 weeks, which may also be the time that neonatal laxity itself diminishes. This is 4 weeks earlier than the accepted time frame when LHA becomes reliable.[6] While not commenting upon the precise mode of onset of LHA, other study has reported similar sensitivities of unilateral LHA (69%) in a population of infants over the age of 3 months.[31] Assessing an asymmetrical response to range of movement is easier than a symmetrical one and may account for the very low sensitivity of bilateral LHA and DDH.
We do not consider bilateral LHA in an infant <8 weeks of age to be an accurate clinical sign in the diagnosis of pathological DDH. Bilateral LHA can be rarely associated with bilateral hip dislocations; however, from a cohort of over 37 000 patients over 10 years, we have had only two cases of bilateral hip dislocations both of whom presented late. It is clearly implausible to justify effective clinical screening for such a rare condition. On the rare occasion where a walking infant presents with a severe bilateral LHA in association with postural or gait abnormality (ie, an increased lumbar lordosis and a waddling Trendelenburg gait), it could signify serious hip pathology and a pelvic radiograph should be arranged and assessed.
The high sensitivity and specificity of unilateral LHA after 8 weeks of age suggests that it is an important clinical sign which should be actively sought. This may be particularly true for the secondary general practitioner/health professional (primary healthcare) clinical hip screening programmes which recommend clinical hip screening at 6–8 weeks of age.[18,32] Detection may allow earlier intervention and potentially reduce the rate of 'late' irreducible hip dislocation presentation. Training into the importance of unilateral LHA presenting after the age of 6–8 weeks of age should be emphasised. Ideally, the clinical examination should be undertaken by small groups of experienced clinicians as wide groups of inexperienced clinicians may miss this important clinical sign. Such experienced small groups have been shown to improve effectiveness of accurate diagnosis in neonatal hip instability in Sweden.[33]
The current recommended 6-week assessment may be too early and may miss the development of the LHA. Delaying the assessment until 8 weeks may be advantageous. This change would require a proper multicentre controlled comparative trial between the different timings (6 weeks vs 8–12 weeks), showing a clear advantage before any change in timing could be recommended. Due to the low incidence of 'pathological' DDH, this series would take many years and would be difficult to organise.
In conclusion, this study identifies a time-dependent association with unilateral LHA in the diagnosis of 'pathological' DDH after the age of 8 weeks. The presence of bilateral LHA in the young infant may be a normal variant in the majority and is a poor screening sign for determining the presence of pathological DDH due to its low sensitivity and poor PPV. LHA should be actively sought after 8 weeks of age and if present should prompt for referral to a specialist (Paediatric Orthopaedic Surgeon or expert hip sonographer) followed by a formal ultrasound or radiographic examination to confirm whether or not the hip is developing in a satisfactory manner.
Sidebar 1
What Is Known About This Topic
- The lack of a practical confirmatory 'gold-standard' clinical or sonographic makes identification of developmental dysplasia of the hip (DDH) difficult.
- The relationship of limitation of hip abduction (LHA) and DDH remains controversial. While LHA has been identified to be present in DDH, the onset of the sign has not been accurately identified.
Sidebar 2
What This Study Adds
- The bilateral LHA sign may be a normal variant in infants and has a low sensitivity and positive predictive value.
- Our study shows the high sensitivity and specificity of unilateral LHA after 8 weeks of age suggesting that it is an important clinical sign which should be actively sought.
References
- Jari S, Paton RW, Srinivasan MS. Unilateral limitation of abduction of the hip. A valuable clinical sign for DDH? J Bone Joint Surg[Br] 2002;84B:104–7.
- Godward S, Dezateux C. Surgery of congenital dislocation of the hip in the UK as a measure of outcome of screening. MRC Working Party on Congenital Dislocation of the Hip. Medical Research Council. Lancet 1998;351:1149–52.
- Terjesan T. ULtrasound as the primary imaging method in the diagnosis of hip dysplasia in children aged <2 years. J Pediatr Orthop 1996;5:123–8.
- Stoffelen D, Urlus M, Molenaers G, et al. Ultrasound, radiographs and clinical symptoms in developmental dislocation of the hip: a study of 170 patients. J Pediatr Orthop B 1995;4:194–9.
- Paton RW, Hinduja K, Thomas CD. The significance of at-risk factors in ultrasound surveillance of developmental dysplasia of the hip. J Bone Joint Surg [Br]2005;87B:1264–6.
- Homer CJ, Balz RD, Hickson GB, et al. American Academy of Pediatrics, Clinical Practice Guideline: Early Detection of Developmental Dysplasia of the Hip. Committee on Quality Improvement, Subcommittee on Developmental Dysplasia of the Hip. Pediatrics 2000;105:896–905.
- Graf R, Tschauner C, Klapsch W. Progress in prevention of late developmental dislocation of the hip by sonographic newborn hip screening—results of a comparative follow-up-study. J Pediatr Orthop B 1993;2:115–21.
- Harcke HT, Clarke NM, Lee MS, et al. Examination of the infant hip with real time ultrasonography. J Ultrasound Med 1984;4:131–7.
- Castelein RM, Dauter AJ, deVlieger M, et al. Natural history of ultrasound hip abnormalities in clinically normal newborns. J Pediatr Orthop 1992;12:423–7.
- Wood MK, Conboy V, Benson MKD. Does early treatment by abduction splintage improve the development of dysplasic but stable hips? J Pediatr Orthop2000;20:302–5.
- Rosendahl K, Markestad T, Lie RT. Developmental dysplasia of the hip. A population based comparison of ultrasound and clinical findings. Acta Paediatr1996;85:64–9.
- Tonnis D. Normal value of the hip joint for the evaluation of X-rays in children and adults. Clin Orthop Relat Res 1976;119:39–47.
- Patel H. Preventative health care: 2001 update: screening and management of developmental dysplasia of the hip in newborns. CMAJ 2001;164:1667–77.
- Shipman SA, Hefand M, Moyer VA, et al. Screening for developmental dysplasia of the hip: as systemic literature review for the US Preventative Services Task Force. Pediatrics 2006;117:e557–76.
- Klisic PJ. Congenital dislocation of the hip—a misleading term: brief report. J Bone Joint Surg 1989;71:136.
- Bialik V, Bialik GM, Blazer S, et al. Developmental dysplasia of the hip: a new approach to incidence. Pediatrics 1999;103:93–9.
- Bache CE, Clegg J, Herron M. Risk factors for developmental dysplasia of the hip: ultrasonographic findings in the neonatal period. J Pediatr Orthop B2002;11:212–18.
- Standing Medical Advisory Committee (SMAC). Screening for the detection of congenital dislocation of the hip. London: Department of Health and Social Security, 1986.
- Jones D. Neonatal detection of developmental dysplasia of the hip. J Bone Joint Surg [Br] 1998;80:943–5.
- Barlow T. Early diagnosis and treatment of congenital dislocation of the hip. J Bone Joint Surg [Br] 1962;44-B:292–301.
- Macnicol MF. Results of a 25 year screening programme for neonatal hip instability. J Bone Joint Surg [Br] 1990;72:1057–60.
- Editorial. Screening for congenital hip dysplasia. Lancet 1991;337:947–8.
- Furnes O, Lie SA, Espehaug B, et al. Hip disease and the prognosis of total hip replacements. A review of 53,698 primary hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg [Br] 2001;83:579–86.
- Palmén K. Preluxation of the hip joint: diagnosis and treatment in the newborn and the diagnosis of congenital dislocation of the hip joint in Sweden during the years 1948–1960. Acta Paediatr 1961;50(Suppl 129):1–71.
- Rosendahl K, Markestad T, Lie RT. Developmental dysplasia of the hip: prevalence based on ultrasound diagnosis. Pediatr Radiol 1996;26:635–9.
- Bialik V, Wiener F. Sonography of suspected developmental dysplasia of the hip: a description of 3624 hips. J Pediatr Orthop 1993;2:152–5.
- Green NE, Griffin PP. Hip dysplasia associated with abduction contracture of the contralateral hip. J Bone Joint Surg [Am] 1982;64:1273–81.
- Wynne-Davies R. Acetabular dysplasia and familial joint laxity: Two etiological factors in congenital dislocation of the hip. J Bone Joint Surg 1970;52-B:704–16.
- Good C, Walker G. The hip in the moulded baby syndrome. J Bone Joint Surg [Br] 1984;66:491–2.
- Buxton RA, Macnicol MF. Infantile skeletal skew: the use of ultrasound in management. J Pediatr Orthop B 2004;13:75–80.
- Castelein RM, Korte J. Limited hip abduction in the infant. J Pediatr Orthop 2001;21:668–70.
- Newborn and Infant Physical Examination (NIPE). http:/nipe.screening.nhs.uk
- Duppe H, Danielsson LG. Screening of neonatal instability and of developmental dislocation of the hip. A Survey of 132,601 Living newborn infants between 1956 & 1999. J Bone Joint Surg [Br] 2002;84-B:878–85.
Τετάρτη 25 Σεπτεμβρίου 2013
Nail Shedding Following Hand, Foot and Mouth Disease
Nail Shedding Following Hand, Foot and Mouth Disease
Zhen Han Tan, Mark Jean-Aan Koh
Arch Dis Child. 2013;98(9):665
A previously well 5-year-old Chinese girl presented to the children's emergency with nail discolouration of 5 days duration. There was no associated pain or history of trauma. She had otherwise just recovered from hand, foot and mouth disease (HFMD) 3 weeks ago. On examination, there was separation of the nail plate from the nail bed, beginning at the proximal nail fold, affecting both thumbs and big toes (figure 1). No other cutaneous lesions were noted, and general examination was unremarkable. The diagnosis of onychomadesis was made, and her parent was reassured that no treatment was required.
Figure 1.
Patient's right thumb showing onychomadesis.
Onychomadesis is defined as a painless spontaneous separation of the nail plate from the bed, beginning at the proximal end with subsequent shedding of the nail as the new nail grows. It can occur idiopathically, after trauma, or in association with serious systemic illnesses, infections and drugs reactions.[1,2] The association between onychomadesis and HFMD was first proposed by Clementz et al,[3] with recent studies of HFMD outbreaks in Spain and Finland providing further supporting evidence.[4]
Onychomadesis occurs as a result of temporary arrest of nail growth at the nail matrix. Other possible mechanisms of onychomadesis in HFMD include inflammation of the nail matrix and intensive hygienic measures resulting in maceration, Candida infection and allergic contact dermatitis.[5] No treatment is required for onychomadesis, and onward referral to specialist is unnecessary. Patients should be reassured that spontaneous regrowth of a new normal nail is usually seen within a few months.
Κυριακή 15 Σεπτεμβρίου 2013
Should We Just Say Yes to Pacifiers?
Should We Just Say Yes to Pacifiers?
William T. Basco, Jr., MD, MS
Jun 28, 2013Pacifier Restriction and Exclusive Breastfeeding
Kair LR, Kenron D, Etheredge K, Jaffe AC, Phillipi CA
Pediatrics. 2013;131:e1101-1107
Study Summary
Kair and colleagues conducted a quasi-experimental study in which they evaluated changes in exclusive breastfeeding rates in a hospital before and after an initiative that involved reducing pacifier access in the newborn nursery. Conflicting evidence has raised the concern that pacifier use interferes with initiation of breastfeeding. Observational studies suggest a potential negative effect of pacifier use on breastfeeding outcomes, whereas randomized trials do not show a difference in breastfeeding outcomes with different times and types of pacifier use. The World Health Organization and the United Nations Children's Fund urge hospitals to implement 10 steps designed to increase the frequency of successful breastfeeding. Among the 10 precepts are:
• Increase maternal education about the benefits of breast-feeding;
• Limit exposure to any food or drink other than breast milk; and
• Avoid pacifiers or other artificial nipples in the newborn nursery.
The large, university teaching hospital where this study was conducted began a program that included 5 of the 10 precepts: initiation of breastfeeding immediately after birth, feeding only breast milk in the hospital, rooming-in of the mother and child, no use of pacifiers, and provision of postdischarge breastfeeding support. The analysis of breastfeeding outcomes covered the latter months of 2010 and the early months of 2011. A changeover month between the 2 periods was not analyzed because staff were in the process of implementing the 5 precepts.
Access to pacifiers was made difficult but not impossible, with employees required to sign for any pacifiers taken from supply and given to an infant. Parents could bring pacifiers to the hospital, and the frequency of this practice was not monitored. The 5 desired breastfeeding behaviors were communicated to parents, including specific discussions about limiting pacifier use. The bulk of the data for this report was obtained from the electronic medical records of the hospital.
The study involved 2249 infants (812 in the "preintervention" group and 1278 in the "postintervention" group). The 2 groups were generally similar except that the postintervention group was more likely to be privately insured than the preintervention group. The medical histories and physical examinations of the infants in both groups were similar. When looking at the primary outcome, the proportion of infants who were exclusively breastfed in the preintervention period was 79% compared with 68% in the postintervention group. This was associated with a 10 percentage-point increase in the proportion of children who were receiving some degree of formula supplementation. Kair and colleagues concluded that restricting access to pacifiers without also restricting access to formula was associated with reduced rates of exclusive breastfeeding.
Viewpoint
This study points out the limitations of quasi-experimental and observational study designs. Certainly, it is important for hospitals to track the outcomes associated with process of care changes. However, implementation of a program such as the Baby-Friendly Hospital Initiative, whether complete or partial, does not occur in a vacuum. System-wide changes are often necessitated by the implementation, along with a great deal of provider and staff education. If an intervention is successful, it can be very difficult to determine which component of the intervention was responsible for success. On the reverse side, when an intervention does not work but was not tightly controlled, it can be difficult to identify the reasons why it failed.
Kair and colleagues seem to think that the failure to entirely limit access to pacifiers and to limit access to formula were associated with the lower percentage of exclusive breastfeeding, but the true reasons for this unexpected change are unknown. A shift towards more privately insured mothers in the postintervention group was identified, but this should have biased the results towards a higher frequency of breastfeeding based on historical epidemiologic data. It makes the change in frequency of exclusive breastfeeding observed at this hospital even more intriguing.
Εγγραφή σε:
Αναρτήσεις (Atom)